|
|
Companies seeking to bolster
their R&D portfolio often need to identify early stage
drugs which an originator/licensor would consider out-licensing,
and make a proactive approach. If they are seeking to license
marketed drugs, they can research a company's existing product
portfolio assessing how much a drug would be worth. The value
of the drug in particular geographic markets is related to
the length of the patent term
before expiry, so knowing this is essential.
Alternatively, a company may invent a drug which they realise
has significant commercial potential, but which does not fit
with their overall strategy. Licensing the drug out is the
ideal way to exploit it without marketing it themselves. The
licensor and potential licensee need to know the worth of
the drug within the disease areas it's indicated.
Each party needs an objective
assessment of the other ahead of negotiation. A useful
indicator when seeking partners is the extent to which they
license in and/or out
within their existing portfolio. This gives an indication
of their experience and attitude to such transactions.
|
